- Home
- LAKE vs CHRS Comparison
LAKE vs CHRS Comparison
Compare LAKE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAKE
- CHRS
- Stock Information
- Founded
- LAKE 1982
- CHRS 2010
- Country
- LAKE United States
- CHRS United States
- Employees
- LAKE N/A
- CHRS N/A
- Industry
- LAKE Industrial Specialties
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAKE Health Care
- CHRS Health Care
- Exchange
- LAKE Nasdaq
- CHRS Nasdaq
- Market Cap
- LAKE 142.3M
- CHRS 159.2M
- IPO Year
- LAKE 1986
- CHRS 2014
- Fundamental
- Price
- LAKE $15.35
- CHRS $1.71
- Analyst Decision
- LAKE Strong Buy
- CHRS Strong Buy
- Analyst Count
- LAKE 3
- CHRS 4
- Target Price
- LAKE $25.00
- CHRS $4.51
- AVG Volume (30 Days)
- LAKE 139.4K
- CHRS 1.2M
- Earning Date
- LAKE 09-09-2025
- CHRS 11-05-2025
- Dividend Yield
- LAKE 0.79%
- CHRS N/A
- EPS Growth
- LAKE N/A
- CHRS N/A
- EPS
- LAKE N/A
- CHRS 1.55
- Revenue
- LAKE $191,631,000.00
- CHRS $272,209,000.00
- Revenue This Year
- LAKE $31.17
- CHRS N/A
- Revenue Next Year
- LAKE $6.62
- CHRS $109.48
- P/E Ratio
- LAKE N/A
- CHRS $1.10
- Revenue Growth
- LAKE 39.13
- CHRS 52.33
- 52 Week Low
- LAKE $12.76
- CHRS $0.66
- 52 Week High
- LAKE $27.28
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LAKE 56.99
- CHRS 69.28
- Support Level
- LAKE $14.70
- CHRS $1.56
- Resistance Level
- LAKE $15.59
- CHRS $1.78
- Average True Range (ATR)
- LAKE 0.42
- CHRS 0.12
- MACD
- LAKE 0.06
- CHRS 0.00
- Stochastic Oscillator
- LAKE 71.22
- CHRS 81.71
About LAKE Lakeland Industries Inc.
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.